Calypte Biomedical Reports Three New - 500 Beiträge pro Seite

[V51]

(BSNS WIRE) Calypte Biomedical Reports Three New Insurance Customers; Continu
s Insurance Market Penetration
Calypte Biomedical Reports Three New Insurance Customers; Continues Insurance Ma
ket Penetration


Business Editors/Health/Medical Writers

ALAMEDA, Calif.--(BUSINESS WIRE)--March 10, 2003--Calypte
Biomedical Corporation (OTCBB:CALY), the developer and marketer of the
only two FDA-approved HIV-1 antibody tests that can be used with urine
samples, today announced that three new insurance customers, SAFECO
Insurance, Shenandoah Life and Life of Georgia have adopted Calypte`s
urine HIV tests.
Nancy Katz, president and CEO of Calypte, stated, "Urine HIV
testing, when combined with other urine tests, offers the most
comprehensive panel of tests available, other than serum; and has been
shown to be an effective option for insurance companies looking to
reduce costs and increase market share. Industry members continue to
show confidence in our product by accepting urine HIV as part of their
regular medical underwriting as well as broadening the age and policy
value requirements to utilize our HIV tests."
In addition to securing new accounts, current clients such as John
Hancock and Fidelity & Guarantee are increasing their urine testing
volume. It is believed that part of the volume expansion is attributed
to companies beginning to utilize "agent collection," a process that
requires insurance agents to collect samples in the field. This will
provide Calypte with an excellent opportunity to leverage a successful
experience with this process with other insurance companies who have
investigated implementing agent collection for urine HIV testing.
"In the fourth quarter, 2002, we observed strong growth of 58%
from our prior quarter for our insurance business," said Anthony
Cataldo, executive chairman of Calypte. "As mentioned during our
fourth quarter earnings conference call, Calypte will continue to
build its distribution channels and expand our customer base to
provide future growth in the first half of 2003. As there is typically
a ramp up period, we would expect to reap increased benefits of this
growth in second half of the year."

About Calypte

Calypte Biomedical Corporation, headquartered in Alameda,
California, is a public healthcare company dedicated to the
development and commercialization of urine-based diagnostic products
and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually
transmitted diseases and other infectious diseases. Calypte`s tests
include the screening EIA and supplemental Western Blot tests, the
only two FDA-approved HIV-1 antibody tests that can be used on urine
samples. The company believes that accurate, non-invasive urine-based
testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an
environment in which testing may be done safely, economically, and
painlessly. Calypte markets its products in countries worldwide
through international distributors and strategic partners. Current
product labeling including specific product performance claims can be
found at www.calypte.com.

Statements in this press release that are not historical facts are
forward-looking statements, including statements regarding future
revenues and sales projections, plans for future financing, the
ability to meet operational milestones, marketing arrangements and
plans, and shipments to and regulatory approvals in international
markets. Such statements reflect management`s current views, are based
on certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and
will be dependent upon a variety of factors, including, but not
limited to, our ability to obtain additional financing that will allow
us to continue our current and future operations and whether demand
for our product and testing service in domestic and international
markets will continue to expand. The Company undertakes no obligation
to publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any
change in the Company`s expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.
Factors that may impact the Company`s success are more fully disclosed
in the Company`s most recent public filings with the U.S. Securities
and Exchange Commission ("SEC"), including its annual report on Form
10-K/A (No.3) for the year ended December 31, 2001 and its subsequent
filings with the SEC.

--30--LR/sf*

CONTACT: Calypte Biomedical Corporation
Pamela South, 510/749-5000
[e-mail]
www.calypte.com
or
Lippert/Heilshorn & Associates
Brendan Lahiff/Kirsten Chapman, 415/433-3777 (IR)
[e-mail]

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY PRODUCT
SOURCE: Calypte Biomedical Corporation

Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com




*** end of story ***

[V51]

wenn ich das richtig verstehe dann -> WOW

Was für Potential.

[biketraum]

Nutzt dem Kurs aber auch nicht!!!!!

[TomSec]

noch nicht